Abstract
Background
Rectal cancer (RC) represents approximately one-third of all colorectal cancer, and its incidence has been increasing worldwide. Nectin-4 has demonstrated oncological effects on several human cancers and has attracted attention as a novel therapeutic target molecule. However, the clinical significance and underlying mechanism in RC remain largely unknown.
Methods
To investigate the prognostic impact of Nectin-4 in localized advanced RC, we first evaluated Nectin-4 expression in 135 tissues from patients with Stage II/III RC using immunohistochemistry. Patients were then categorized into 2 groups according to Nectin-4 status. Subsequently, we evaluated the clinical impact of Nectin-4 on oncological outcomes using survival calculations and uni-/multivariate analysis. Furthermore, we performed in-vitro assays to elucidate the underlying mechanisms of Nectin-4 in cell proliferation.
Results
Patients with high Nectin-4 expression exhibited worse postoperative prognosis than those with low (OS: P = 0.002, RFS: P = 0.002). Multivariate analysis revealed that Nectin-4 expression was a significant independent prognostic factor in RC (OS: P = 0.002, RFS: P = 0.002). In addition, the Nectin-4 status stratified post-recurrence survival in patients who received chemotherapy for postoperative relapse (P = 0.023). Nectin-4 silencing by siRNA significantly inhibited RC cell proliferation, furthermore, the combination of Nectin-4 silencing and 5-FU resulted in a synergistic antitumor effect.
Discussion
We have showcased the clinical impact and biological value of Nectin-4 in RC. Our findings could provide a guidepost for further clinical trials to establish individualized treatment for RC and act as a key to opening the door to genome-based precision medicine.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
